卵巢癌血清CCL18、HK10水平变化及与肿瘤恶性生物学行为的关系  

The relationship between the changes in serum levels of CC-chemokine ligand 18 and human kallikrein 10 and the malignant biological behavior of ovarian cancer

作　　者：陈秀英[1] 陈娜[1] 崔建涛 高娜[1] 李晓丹 张玉丽 张士表[1] 谢昱伟 CHEN Xiuying;CHEN Na;CUI Jiantao;GAO Na;LI Xiaodan;ZHANG Yuli;ZHANG Shibiao;XIE Yuwei(Department of Gynecology,Cangzhou Hospital of Integrated Traditional Chinese and Western of Hebei Province,Cangzhou 061000,Hebei,China)

机构地区：[1]河北省沧州中西医结合医院妇科,河北沧州061000

出　　处：《中国性科学》2024年第10期77-82,共6页Chinese Journal of Human Sexuality

基　　金：河北省中医药管理局2021年度中医药类科研计划(2021296)。

摘　　要：目的探讨卵巢癌血清趋化因子18(CCL18)、人激肽释放酶10(HK10)水平变化及与肿瘤恶性生物学行为的关系。方法选取2018年1月至2023年4月河北省沧州中西医结合医院收治的100例卵巢癌患者作为研究组,50例良性卵巢肿瘤患者作为对照组,50名健康志愿者作为健康组。比较三组血清CCL18、HK10水平,研究组不同肿瘤恶性生物学行为患者血清CCL18、HK10水平,研究组不同化疗灵敏度患者化疗前和化疗3、6个周期后血清CCL18、HK10水平变化值,分析化疗前后血清CCL18、HK10水平变化值与化疗灵敏度的关系及对化疗灵敏度的预测价值。结果研究组血清CCL18、HK10水平均高于对照组、健康组(P<0.05)。研究组不同国际妇产科联盟(FIGO)分期、淋巴结转移、肌层浸润程度血清CCL18和HK10水平、不同分化程度血清HK10水平比较,差异具有统计学意义(P<0.05)。研究组化疗不灵敏患者CCL18△1(△1为化疗3个周期后与化疗前变化值的绝对值)、HK10△1均低于化疗灵敏患者(P<0.05)。CCL18△1、HK10△1联合检测的曲线下面积(AUC)显著高于单一指标(P<0.05)。结论卵巢癌血清CCL18、HK10水平升高与肿瘤恶性生物学行为关系密切,且其变化值能够辅助临床预测化疗灵敏度,两者联合检测具有较高的化疗灵敏度预测价值。Objective To investigate the changes in serum levels of CC-chemokine ligand 18(CCL18)and human kallikrein 10(HK10)in ovarian cancer and their relationship with malignant biological behavior of the tumor.Methods A total of 100 ovarian cancer patients admitted to the Cangzhou Hospital of Integrated Traditional Chinese and Western of Hebei Province from January 2018 to April 2023 were selected as the study group.A total of 50 patients with benign ovarian tumors were selected as the control group,and 50 healthy volunteers were selected as the healthy group.The levels of serum CCL18 and HK10 in the three groups,the levels of serum CCL18 and HK10 in patients with different malignant biological behaviors in the study group,and the changes in serum CCL18 and HK10 levels before and after chemotherapy for 3 and 6 cycles in patients with different chemotherapy sensitivity in the study group were compared.The relationship between the changes in serum CCL18 and HK10 levels before and after chemotherapy and chemotherapy sensitivity,as well as their predictive value for chemotherapy sensitivity were analyzed.Results The levels of serum CCL18 and HK10 in the study group were both higher than those in the control group and the healthy group(P<0.05).Comparison of the levels of serum CCL18 and HK10 in patients with different international federation of gynecology and obstetrics(FIGO)stages,lymph node metastasis,and muscle invasion,as well as the levels of serum HK10 in patients with different degrees of differentiation in the study group showed statistically significant differences(P<0.05).The CCL18△1(△1 is the absolute value of the change between three cycles of chemotherapy and before chemotherapy)and HK10△1 of the insensitive patients in the study group were lower than those of the sensitive patients(P<0.05).The area under the curve(AUC)of the combined detection of CCL18△1 and HK10△1 was significantly greater than that of a single index(P<0.05).Conclusions The elevated levels of serum CCL18 and HK10 in ovarian cancer a

关 键 词：卵巢癌 趋化因子18 人激肽释放酶10 恶性生物学行为 

分 类 号：R711[医药卫生—妇产科学]